Image may be NSFW.
Clik here to view.
A panel of experts from the European Medicines Agency issued a positive recommendation today for Novo Nordisk‘s (NYSE:NVO) once-weekly diabetes drug, Ozempic.
The committee’s recommendation will need to be endorsed by the European Commission before the insulin-maker’s product can be formally marketed in the EU.
Get the full story at our sister site, Drug Delivery Business News.
The post European committee backs Novo Nordisk’s once-weekly Type II diabetes therapy appeared first on MassDevice.
